J. Iuliucci

发表

In vivo treatment with a monoclonal chimeric anti‐CD4 antibody results in prolonged depletion of circulating CD4+ cells in chimpanzees

P. Daddona, G. Riethmüller, A. Lobuglio, 1993, Clinical and experimental immunology.

Monoclonal Antibodies to Platelet Glycoprotein IIb/IIIa as Antithrombotic Agents a

H. Weisman, J. Ghrayeb, H. Gold, 1991, Annals of the New York Academy of Sciences.

SAR of Carbon‐Linked, 2‐Substituted Purines: Synthesis and Characterization of AP23451 as a novel Bone‐Targeted Inhibitor of Src Tyrosine Kinase With In Vivo Anti‐Resorptive Activity

R. Bohacek, L. Xing, B. Boyce, 2008, Chemical biology & drug design.

Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers

T. Clackson, S. Oliver, D. Dalgarno, 2001, Journal of clinical pharmacology.

Pharmacologically regulated Fas-mediated death of adoptively transferred T cells in a nonhuman primate model.

S. Heimfeld, T. Clackson, S. Riddell, 2004, Blood.

Src Inhibitors in Metastatic Bone Disease

L. Xing, T. Yamashita, B. Boyce, 2006, Clinical Cancer Research.

Future Anti‐Catabolic Therapeutic Targets in Bone Disease

L. Xing, B. Boyce, T. Sawyer, 2006, Annals of the New York Academy of Sciences.

Potent Antitumor Activity of AP24534, an Orally Active Inhibitor of Bcr-Abl Variants Including T315I, in In Vitro and In Vivo Models of Chronic Myeloid Leukemia (CML).

T. Clackson, B. Druker, A. Corbin, 2007 .

Inhibition of human platelet function in vivo with a monoclonal antibody. With observations on the newly dead as experimental subjects.

B. Coller, L. Scudder, J. Iuliucci, 1988, Annals of internal medicine.

Cartilage-staining technique for the examination of unskinned fetal rat specimens previously processed with alizarin red S.

J. Iuliucci, R. Carrano, J. Boardman, 1984, Teratology.

Morphine-induced fetal malformations. II. Influence of histamine and diphenhydramine.

J. Iuliucci, R. Gautieri, John D. Iuliucci, 1971, Journal of pharmaceutical sciences.

Discovery of 3-[2-(imidazo[1,2-b]pyridazin-3-yl)ethynyl]-4-methyl-N-{4-[(4-methylpiperazin-1-yl)methyl]-3-(trifluoromethyl)phenyl}benzamide (AP24534), a potent, orally active pan-inhibitor of breakpoint cluster region-abelson (BCR-ABL) kinase including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2010, Journal of medicinal chemistry.

Ridaforolimus (AP23573; MK-8669), a Potent mTOR Inhibitor, Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011, Molecular Cancer Therapeutics.

Preclinical Development Ridaforolimus ( AP 23573 ; MK-8669 ) , a Potent mTOR Inhibitor , Has Broad Antitumor Activity and Can Be Optimally Administered Using Intermittent Dosing Regimens

T. Clackson, L. Berk, V. Rivera, 2011 .

Src inhibitors: genomics to therapeutics

T. Sawyer, D. Dalgarno, J. Iuliucci, 2001, Expert opinion on investigational drugs.

9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation.

G. Daley, T. Clackson, M. Azam, 2009, Journal of medicinal chemistry.

Orally Active Inhibitors of the Imatinib Resistant Bcr-Abl Mutant T315I.

T. Clackson, B. Druker, A. Corbin, 2006 .

Discovery of 5-(arenethynyl) hetero-monocyclic derivatives as potent inhibitors of BCR-ABL including the T315I gatekeeper mutant.

Wei-Sheng Huang, Jan Romero, Shuangying Liu, 2011, Bioorganic & medicinal chemistry letters.

In vitro and in vivo activity of ATP-based kinase inhibitors AP23464 and AP23848 against activation-loop mutants of Kit.

B. Druker, M. Heinrich, A. Corbin, 2005, Blood.

Pharmacologic control of a humanized gene therapy system implanted into nude mice.

Shannon R. Magari, V. Rivera, M. Gilman, 1997, The Journal of clinical investigation.

Structure-based design of an osteoclast-selective, nonpeptide src homology 2 inhibitor with in vivo antiresorptive activity.

M. Hatada, S. Violette, R. Bohacek, 2000, Proceedings of the National Academy of Sciences of the United States of America.

Regulation of bone remodeling and emerging breakthrough drugs for osteoporosis and osteolytic bone metastases.

William Shakespeare, Brendan F Boyce, L. Xing, 2003, Kidney international. Supplement.

Abstract 3623: Efficacy and pharmacodynamic analysis of AP26113, a potent and selective orally active inhibitor of Anaplastic Lymphoma Kinase (ALK)

Juan J. Miret, Wei-Sheng Huang, Shuangying Liu, 2010 .

Novel accessory skull bone in fetal rats after exposure to aspirin.

J. Iuliucci, R. Carrano, J. Boardman, 1984, Teratology.